Evaluation of the use of Hydroxychlorochine in Chinese flu

Evaluation of the use of Hydroxychlorochine in patients with discrete form of Covid-19: randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-3k4wxb

Enrollment

Unknown

Registered

2020-05-05

Start date

2020-05-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non specified coronavirus infection/ coronavirus

Interventions

1. Control group - 15 participants The Control group will receive proper COVID19 treatment but will not receive hydroxychloroquine, chloroquine, azithromycin, or another macrolide. PT-BR EN 2. G1 - 15

Drug

D03.633.100.810.050.180.350

D02.540.576.500.992.050

Eligibility

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Positive RT-PCR; age> 18 years; discrete classification (without signs of dyspnea, and oximetry greater than 93%)

Exclusion criteria

Exclusion criteria: Need for ICU on day 0; allergy to hydroxychloroquine or azithromycin; retinopathy; G6PD deficiency; QT extension; lactation; pregnancy; hepatic insufficiency; acute renal failure; patients who did not sign the informed consent

Design outcomes

Primary

Measure	Time frame
Negative viral load; RT-PCR was taken from a negative oropharynx swab; the RT-PCR value must be literally zero (0) for the patient to be considered cured	—

Secondary

Measure	Time frame
No secondary outcomes	—

Countries

Brazil

Contacts

Public ContactMarcos Aurelio Barboza de Oliveira

Hospital Santo Antônio

maboliveira@gmail.com+55-066-35171800

Outcome results

None listed

Source: REBEC (via WHO ICTRP)